Abstract:Background and Hypothesis Schizophrenia (SCZ) is associated with complex crosstalk between the gut microbiota and host metabolism, but the underlying mechanism remains elusive. Investigating the aberrant neurotransmitter processes reflected by alterations identified using multiomics analysis is valuable to fully explain the pathogenesis of SCZ. Study Design We conducted an integrative analysis of multiomics data, including the serum metabolome, fecal metagenome, single nucleotide polymorphism data, and neuroimaging data obtained from a cohort of 127 drug-naive, first-episode SCZ patients and 92 healthy controls to characterize the microbiome-gut-brain axis in SCZ patients. We used pathway-based polygenic risk score (PRS) analyses to determine the biological pathways contributing to genetic risk and mediation effect analyses to determine the important neuroimaging features. Additionally, a random forest model was generated for effective SCZ diagnosis. Study Results We found that the altered metabolome and dysregulated microbiome were associated with neuroactive metabolites, including gamma-aminobutyric acid (GABA), tryptophan, and short-chain fatty acids. Further structural and functional magnetic resonance imaging analyses highlighted that gray matter volume and functional connectivity disturbances mediate the relationships between Ruminococcus_torgues and Collinsella_aerofaciens and symptom severity and the relationships between species Lactobacillus_ruminis and differential metabolites l-2,4-diaminobutyric acid and N-acetylserotonin and cognitive function. Moreover, analyses of the Polygenic Risk Score (PRS) support that alterations in GABA and tryptophan neurotransmitter pathways are associated with SCZ risk, and GABA might be a more dominant contributor. Conclusions This study provides new insights into systematic relationships among genes, metabolism, and the gut microbiota that affect brain functional connectivity, thereby affecting SCZ pathogenesis.

Metabolomic Identification Of Exosome-Derived Biomarkers For Schizophrenia: A Large Multicenter Study

Exosome and Exosomal Contents in Schizophrenia

Dysregulation of Serum Exosomal Lipid Metabolism in Schizophrenia: A Biomarker Perspective

Genome-Wide, Integrative Analysis Implicates Exosome-Derived MicroRNA Dysregulation in Schizophrenia.

Metabolomic Identification of Serum Exosome-Derived Biomarkers for Bipolar Disorder

Multiomics Analyses Reveal Microbiome–Gut–Brain Crosstalk Centered on Aberrant Gamma-Aminobutyric Acid and Tryptophan Metabolism in Drug-Naïve Patients with First-Episode Schizophrenia

Alteration of lipids and amino acids in plasma distinguish schizophrenia patients from controls: A targeted metabolomics study

Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia.

Exosome Transplantation from Patients with Schizophrenia Causes Schizophrenia-Relevant Behaviors in Mice: an Integrative Multi-omics Data Analysis.

Integrated Untargeted Fecal Metabolomics and Gut Microbiota Strategy for Screening Potential Biomarkers Associated with Schizophrenia

Potential Plasma Biomarker Panels Identification for the Diagnosis of First-Episode Schizophrenia and Monitoring Antipsychotic Monotherapy with the Use of Metabolomics Analyses

Profiling expressing features of surface proteins on single-exosome in first-episode Schizophrenia patients: a preliminary study

Plasma Metabolomics of Schizophrenia with Cognitive Impairment: A Pilot Study.

Identifying crucial biomarkers in peripheral blood of schizophrenia and screening therapeutic agents by comprehensive bioinformatics analysis

Schizophrenia Shows A Unique Metabolomics Signature in Plasma

Potential metabolite markers of schizophrenia

The identification of novel schizophrenia-related metabolites using untargeted lipidomics

Identification of Potential Blood Biomarkers for Early Diagnosis of Schizophrenia Through RNA Sequencing Analysis

Identification of Peripheral Blood Mirna Biomarkers in First-Episode Drug-Free Schizophrenia Patients Using Bioinformatics Strategy.

Integrated Transcriptome Analysis Reveals Novel Molecular Signatures for Schizophrenia Characterization.

GC-MS Based Metabolomics Identification of Possible Novel Biomarkers for Schizophrenia in Peripheral Blood Mononuclear Cells.